Anzeige
Erschienen in:
01.11.2015 | Originalien
Optimized testing for C. trachomatis DNA in synovial fluid samples in clinical practice
Erschienen in: Zeitschrift für Rheumatologie | Ausgabe 9/2015
Einloggen, um Zugang zu erhaltenAbstract
Aim
No standardized polymerase chain reaction (PCR) assay is available for detection of Chlamydia trachomatis (C. tr.) in synovial fluid (SF) for diagnostic use in clinical practice. This study tested the performance of two optimized molecular biology methods, to determine which is best suited for detecting C. tr. in SF clinical samples from patients with various rheumatologic diseases.
Methods
Two DNA extraction methods, i.e., (1) alkaline lysis and (2) QIAEX II Gel Extraction Kit® + cetyltrimethylammonium bromide (CTAB; Qiagen, Hilden, Germany), and C. tr.-omp1-152 bp PCR were tested in SF samples from a total of 329 patients with the following diagnoses: reactive arthritis (ReA; n = 10, 4 patients had posturethritic ReA), undifferentiated arthritis (UA; n = 66), rheumatoid arthritis (RA; n = 169), psoriatic arthritis (PSA; n = 12), and osteoarthritis (OA) n = 72.
Results
In SF samples, C. tr.-omp1-152 bp PCR in combination with alkaline lysis DNA extraction allowed detection of more C. tr.-positive samples: 3/10 (30 %) ReA patients (all with posturethritic ReA) and 20/66 (38 %) UA patients were positive, compared to the 0/10 (0 %) patients with ReA and 1/66 (2 %) with UA detected using the QIAEX II Gel Extraction Kit® + CTAB. Moreover, 2/12 (17 %) SF samples from PSA patients tested positive with alkaline lysis. All samples from patients with OA and RA tested negative.
Conclusion
Alkaline lysis in combination with C. tr.-omp1-152 bp PCR emerged as the most sensitive method for identification of C. tr. in clinical SF samples.